Literature DB >> 21997350

Association between recency of last pregnancy and biologic subtype of breast cancer.

Melissa Pilewskie1, Polina Gorodinsky, Angela Fought, Nora Hansen, Kevin Bethke, Jacqueline Jeruss, Denise Scholtens, Seema A Khan.   

Abstract

BACKGROUND: Breast cancers (BCs) diagnosed after a recent pregnancy display features associated with poor prognosis, including hormone receptor negativity, but other tumor markers have not been examined. We sought to define the tumor marker profile of these cancers, including HER-2 and p53 expression, and examine the time interval over which this adverse profile is observed, relative to last pregnancy.
METHODS: A prospectively maintained database was reviewed to identify women with a BC diagnosis between 1998 to 2011. Parous women were categorized on the basis of the interval between pregnancy and BC diagnosis; 0-2 years, >2-5 years, >5-10 years, and >10-15 years. Tumor characteristics of parous cases were compared to those of nulliparous BC patients, who were frequency matched by age.
RESULTS: A total of 175 parous and 114 nulliparous women were identified. Women who were 0-2 years from last parity at the time of BC diagnosis were the only group who were more likely than control women to have grade 3 tumors (P<0.01), positive lymph nodes (P=0.02), and triple negative tumors (P=0.01, odds ratio 3.2, 95% confidence interval 1.2-8.5). There was no difference noted in HER-2 or p53 status relative to interval from pregnancy.
CONCLUSIONS: BC diagnosed within 2 years of pregnancy is more likely to have poor prognostic features and to be triple negative. More work is needed to delineate the time frame of pregnancy-associated BC and to define them on a molecular level, so as to devise better prevention and therapy for this devastating problem.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21997350     DOI: 10.1245/s10434-011-2104-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  19 in total

1.  Placenta-breast cancer cell interactions promote cancer cell epithelial mesenchymal transition via TGFβ/JNK pathway.

Authors:  Gali Epstein Shochet; Shelly Tartakover-Matalon; Liat Drucker; Metsada Pasmanik-Chor; Meir Pomeranz; Ami Fishman; Michael Lishner
Journal:  Clin Exp Metastasis       Date:  2014-10-15       Impact factor: 5.150

2.  Clinicopathological features and prognosis of pregnancy associated breast cancer - a matched case control study.

Authors:  Lilla Madaras; Kristóf Attila Kovács; Attila Marcell Szász; István Kenessey; Anna-Mária Tőkés; Borbála Székely; Zsuzsanna Baranyák; Orsolya Kiss; Magdolna Dank; Janina Kulka
Journal:  Pathol Oncol Res       Date:  2013-12-20       Impact factor: 3.201

3.  Risk factors for pregnancy-associated breast cancer: a report from the Nigerian Breast Cancer Study.

Authors:  Ningqi Hou; Temidayo Ogundiran; Oladosu Ojengbede; Imran Morhason-Bello; Yonglan Zheng; James Fackenthal; Clement Adebamowo; Imaria Anetor; Stella Akinleye; Olufunmilayo I Olopade; Dezheng Huo
Journal:  Ann Epidemiol       Date:  2013-07-20       Impact factor: 3.797

4.  Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer.

Authors:  Traci R Lyons; Virginia F Borges; Courtney B Betts; Qiuchen Guo; Puja Kapoor; Holly A Martinson; Sonali Jindal; Pepper Schedin
Journal:  J Clin Invest       Date:  2014-08-18       Impact factor: 14.808

5.  Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women.

Authors:  Laura C Collins; Shari Gelber; Jonathan D Marotti; Sarah White; Kathryn Ruddy; Elena F Brachtel; Lidia Schapira; Steven E Come; Virginia F Borges; Pepper Schedin; Ellen Warner; Taylor Wensley; Rulla M Tamimi; Eric P Winer; Ann H Partridge
Journal:  Oncologist       Date:  2015-05-29

6.  Risk factors for uncommon histologic subtypes of breast cancer using centralized pathology review in the Breast Cancer Family Registry.

Authors:  Meghan E Work; Irene L Andrulis; Esther M John; John L Hopper; Yuyan Liao; Fang Fang Zhang; Julia A Knight; Dee W West; Roger L Milne; Graham G Giles; Teri A Longacre; Frances O'Malley; Anna Marie Mulligan; Melissa C Southey; Hanina Hibshoosh; Mary Beth Terry
Journal:  Breast Cancer Res Treat       Date:  2012-04-25       Impact factor: 4.872

Review 7.  Multidisciplinary Management of Breast Cancer During Pregnancy.

Authors:  Shlomit Strulov Shachar; Kristalyn Gallagher; Kandace McGuire; Timothy M Zagar; Aimee Faso; Hyman B Muss; Raeshall Sweeting; Carey K Anders
Journal:  Oncologist       Date:  2017-02-23

8.  Association of Parity and Time since Last Birth with Breast Cancer Prognosis by Intrinsic Subtype.

Authors:  Xuezheng Sun; Hazel B Nichols; Chiu-Kit Tse; Mary B Bell; Whitney R Robinson; Mark E Sherman; Andrew F Olshan; Melissa A Troester
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-11-06       Impact factor: 4.254

9.  Hypothesized role of pregnancy hormones on HER2+ breast tumor development.

Authors:  Giovanna I Cruz; María Elena Martínez; Loki Natarajan; Betsy C Wertheim; Manuela Gago-Dominguez; Melissa Bondy; Adrian Daneri-Navarro; María Mercedes Meza-Montenegro; Luis Enrique Gutierrez-Millan; Abenaa Brewster; Pepper Schedin; Ian K Komenaka; J Esteban Castelao; Angel Carracedo; Carmen M Redondo; Patricia A Thompson
Journal:  Breast Cancer Res Treat       Date:  2012-11-08       Impact factor: 4.872

10.  Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer.

Authors:  Eryn B Callihan; Dexiang Gao; Sonali Jindal; Traci R Lyons; Elizabeth Manthey; Susan Edgerton; Alexander Urquhart; Pepper Schedin; Virginia F Borges
Journal:  Breast Cancer Res Treat       Date:  2013-02-22       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.